Hutchmed (China) Limited (HCM)

ORD USD0.10

Sell: 216.00p|Buy: 225.00p|Change: 6.00 (2.78%)

Open

211.00p

Previous close

216.00p

Trade high

230.00p

Volume

106,138

Year high

292.00p

Year low

185.50p

Dividend yield

–

Market capitalisation

£1.91 bn

P/E ratio

5.39

ISIN

KYG4672N1198

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPPand can be used with Dividend reinvestment

Share price

Performance 31/03/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

	Total return (%)
Hutchmed (China) Limited	0.00
More...

Company profile

HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.

Sector

Healthcare

News

Recent trades

Date	Time	Price	Quantity	Value (£)
01/04/2026	04:22:48	220.8	25,000	55,200.00
01/04/2026	03:44:05	220.69	25,000	55,172.50
01/04/2026	04:35:21	222	5,380	11,943.60
01/04/2026	04:09:53	225	0	0.00
01/04/2026	04:09:53	225	4	9.00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.